ACETATO DE ULIPRISTAL EN EL MANEJO DE LA MIOMATOSIS UTERINA SINTOMÁTICA. UNA REVISIÓN BIBLIOGRÁFICA

Abstract

Objective. To perform a literature review on the use of ulipristal acetate (UPA) in the management of symptomatic uterine myomatosis. To evaluate the efficacy and safety of the drug, in order to avoid serious adverse effects such as liver failure. Methods. We collected scientific articles performed in symptomatic women with uterine myomatosis undergoing management with UPA. The search was carried out in high impact databases such as PubMed, Taylor&Francis, Springer, Elsevier, etc. At the conclusion of the search and based on the eligibility criteria, only 39 articles met the inclusion criteria and were selected. Results. According to the studies analyzed, the 14 articles present favorable results in relation to the improvement of symptoms and quality of life of the patients, since it was possible to control uterine bleeding, raise hemoglobin levels, reduce the size and volume of the fibroids, without presenting any serious effect that would lead to the interruption of the treatment. Only one study identified nine cases of severe liver damage, of which five cases ended in liver transplantation and the others reported resolution of the liver injury after discontinuation of treatment. Conclusion. The use of UPA is considered an effective treatment in this pathology. The serious adverse effects shown in the studies proved to be inconclusive because the presence of liver injury or elevation of transaminases prior to treatment was demonstrated. However, new recommendations for the use of the drug were published.